Delving into the Latest Updates on Dendritic cell vaccine(Medigene Immunotherapies GmbH) with Synapse

A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal melanoma not cureable with local therapy and needing systemic therapy. IKKb-matured Dendritic Cells loaded with autologous tumor-RNA + RNA coding for defined antigens and driver mutations will be added to a standard therapy chosen by the tumor board (either checkpoint blockade or chemotherapy).

Start Date24 Jun 2020

Sponsor / Collaborator

Hasumi International Research Foundation Bulgaria

JPRN-jRCTc031190099 / CompletedPhase 2IIT

A clinical trial on the efficacy of combination therapy with immune-cell therapy(dendritic cell vaccine) and immune check point inhibitor for malignant tumor - Combination therapy with immune-cell therapy and immune check point inhibitor

Start Date23 Jun 2020

Sponsor / Collaborator-

100 Clinical Results associated with Dendritic cell vaccine(Medigene Immunotherapies GmbH)

Login to view more data

100 Translational Medicine associated with Dendritic cell vaccine(Medigene Immunotherapies GmbH)

Login to view more data

100 Patents (Medical) associated with Dendritic cell vaccine(Medigene Immunotherapies GmbH)

Login to view more data

425

Literatures (Medical) associated with Dendritic cell vaccine(Medigene Immunotherapies GmbH)

31 Dec 2024·Human Vaccines & Immunotherapeutics

Bibliometric analysis of dendritic cell-based vaccines over the past 15 years

Article

Author: Wu, Yinghua ; Liu, Bo ; Long, Zhi ; Lu, Jiping ; Zhong, Liangchen

Dendritic cells, which are crucial for inducing T-cell responses, are pivotal in current immunotherapy strategies aiming to replenish depleted T cells within the tumor microenvironment to combat tumors. Consequently, dendritic cell vaccine-based cancer therapies have garnered significant attention. Through bibliometric analysis, we examined research trends in this field. We searched the Web of Science core database and identified 16,476 articles on dendritic cell-based vaccines published from January 1, 2009, to December 30, 2023. The United States leads in this research domain, with Emory University being a prominent collaborator. The Journal of Immunology is the primary publication outlet, and Banchereau, J emerges as the most influential author. Recent hot keywords include nanoparticle, delivery, cancer vaccine, and clinical trial, indicating that cancer immunotherapy research, especially dendritic cell-based vaccines, is poised to become a future trend and hotspot.

01 Dec 2024·Asia-Pacific Journal of Clinical Oncology

The clinical utility of autologous tumor lysate‐loaded dendritic cell vaccination for patients with glioma: A systematic review and meta‐analysis

Review

Author: Arab, Shayan ; Ahmadpour, Sajjad ; Mirjani, Mohammad Sina ; Minaee, Poriya ; Delbari, Pouria ; Eazi, SeyedMohammad ; Ahmadvand, Muhammad Hussain ; Habibi, Mohammad Amin

AbstractBackgroundDendritic cell (DC) vaccines show promise for glioma treatment, but optimal use remains uncertain. This meta‐analysis examined DC vaccine efficacy and safety for gliomas.MethodsThis systematic review and meta‐analysis study was conducted using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses. From the date of inception to October 23, 2023, electronic databases PubMed, Embase, Web of Science, and Scopus have been thoroughly evaluated.ResultsA total of 12 studies with 998 patients and a mean age ranging from 40.2 to 56 years were included. Across 12 articles, DC vaccine 6‐month overall survival (OS) was 100% [95% confidence interval {95%CI}: 100%–100%]. Respectively, 12‐month OS reported 75% [95%CI: 65%–85%] but declined to 32% [95%CI: 20%–43%] for 24‐month OS. 6‐ and 12‐month progression‐free survival reached 49% [95%CI: 21%–77%] and 19% [95%CI:8%–30%]. Studying radiological outcomes shows that complete response and partial response rates were 13% [95%CI: 17%–42%], and 26% [95%CI: 10%–42%], though stable disease reached 33% [95%CI: 15%–51%], suggesting predominant antineoplastic effects. The progressive disease rate also was 24% [95%CI: 9%–57%].ConclusionsIn gliomas, DC vaccinations show a temporary efficacy; stability is more prevalent than regression. Impacts favor decreased resistance to early disease. Enhancing efficacy remains critical. Early therapy can be enhanced by appropriate supplementary therapy integration.

15 Oct 2024·International Journal of Cancer

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients

Article

Author: Hlavackova, Eva ; Dusek, Vitezslav ; Kubatova, Jana ; Jezova, Marta ; Mazanek, Pavel ; Dubska, Lenka Zdrazilova ; Demlova, Regina ; Polaskova, Kristyna ; Vejmelkova, Klara ; Kuttnerova, Zuzana ; Palova, Hana ; Turekova, Terezia ; Pokorna, Petra ; Pavelka, Zdenek ; Mlnarikova, Marie ; Mudry, Peter ; Balaz, Martin ; Slaby, Ondrej ; Sterba, Jaroslav ; Pilatova, Katerina Cerna ; Kyr, Michal ; Valik, Dalibor ; Tinka, Pavel ; Kozakova, Sarka ; Kellnerova, Renata ; Merta, Tomas

AbstractA lot of hope for high‐risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single‐agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high‐risk solid tumors using the N‐of‐1 approach in real‐world scenario. A total of 160 evaluable events occurred in 48 patients during the 4‐year follow‐up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check‐point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.

100 Deals associated with Dendritic cell vaccine(Medigene Immunotherapies GmbH)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 2	-	Ludwig-Maximilians-Universität München	-
Prostatic Cancer	Phase 2	-	University of Oslo	-
Prostatic Cancer	Phase 2	-	MediGene AG	-
Acute Myeloid Leukemia	Discovery	NO	MediGene AG	01 Mar 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SITC2015	Not Applicable	Melanoma	5	Dendritic Cell Vaccine + High Dose IL-2 + Taurolidine	brjwufvnwu(hjzpggxcin) = qhkomhfgfo iozzusihva (ookjkgzahq )	Positive	04 Nov 2015
				High Dose IL-2	brjwufvnwu(hjzpggxcin) = kvjuuotasn iozzusihva (ookjkgzahq )